Combined micro-osmotic pump infusion and intracerebroventricular injection to study FGF1 signaling pathways in the mouse brain

Intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) elicits remission of diabetic hyperglycemia in rodent models of type 2 diabetes. Here, we present an optimized protocol to study the intracellular signaling pathways underlying the FGF1-induced sustained glucose lowering in the mouse brain. This protocol combines icv injection of FGF1 and osmotic mini-pump infusion of U0126, an inhibitor of MAPK/ERK signaling. We describe the surgical procedure and verification of U0126 inhibition of FGF1-stimulated hypothalamic MAPK/ERK signaling via western blot.

Jenny M. Brown, Bao Anh Phan, Nadia Aalling, Gregory J. Morton, Michael W. Schwartz, Jarrad M. Scarlett

jenny.brown@sund.ku.dk (J.M.B.)
jarrad.scarlett@seattlechildrens.org (J.M.S.)

Highlights
Protocol for investigating cellular mechanisms underlying FGF1-induced diabetes remission

Simultaneous icv injection and osmotic pump infusion into the third ventricle of mice

Near-infrared western blot to quantify MAPK/ERK signaling in hypothalamic extracts
Protocol
Combined micro-osmotic pump infusion and intracerebroventricular injection to study FGF1 signaling pathways in the mouse brain

Jenny M. Brown,1,2,4,* Bao Anh Phan,1 Nadia Aalling,2 Gregory J. Morton,1 Michael W. Schwartz,1 and Jarrad M. Scarlett1,3,5,*

1Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA
2Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark
3Department of Pediatric Gastroenterology and Hepatology, Seattle Children’s Hospital, Seattle, WA 98145, USA
4Technical contact
5Lead contact
*Correspondence: jenny.brown@sund.ku.dk (J.M.B.), jarrad.scarlett@seattlechildrens.org (J.M.S.)
https://doi.org/10.1016/j.xpro.2022.101329

SUMMARY
Intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) elicits remission of diabetic hyperglycemia in rodent models of type 2 diabetes. Here, we present an optimized protocol to study the intracellular signaling pathways underlying the FGF1-induced sustained glucose lowering in the mouse brain. This protocol combines icv injection of FGF1 and osmotic mini-pump infusion of U0126, an inhibitor of MAPK/ERK signaling. We describe the surgical procedure and verification of U0126 inhibition of FGF1-stimulated hypothalamic MAPK/ERK signaling via western blot.
For complete details on the use and execution of this protocol, please refer to Brown et al. (2021).

BEFORE YOU BEGIN
Stereotaxic delivery of compounds into the central nervous system has transformed our understanding of the role of the brain in the regulation of energy and glucose homeostasis. Ventricular cannulation with a dual-port guide cannula allows for both single, acute intracerebroventricular (icv) FGF1 injections and continuous infusion of bioactive compounds as a tool with which to assess the role of specific intracellular signaling pathways in the brain response to FGF1 (Bentsen et al., 2020; Brown et al., 2019; Scarlett et al., 2016, 2019). The protocol below describes the implantation of a dual-port guide cannula targeting the third ventricle in mice, thus enabling icv FGF1 injection followed immediately by continuous icv infusion of the MAP/ERK inhibitor U0126 for 24 h. This protocol can be optimized for infusion into virtually any brain region, potentially with any combination of 2 compounds. For detailed modifications to the protocol refer to (Bentsen et al., 2020).

Prepare surgical instruments and equipment

© Timing: 1–3 h

1. Sterilize surgical tools, cannula, obturator, screws, gauze, and cotton swabs.
2. Set up stereotaxic system and connect controller unit.
3. Fill isoflurane unit and connect oxygen and vacuum lines.
4. Turn on bead sterilizer.
5. Put on appropriate Personal Protective Equipment for surgery per institutional guidelines.
6. Create sterile field.
7. Place gauze, scalpel, and surgical supplies onto sterile field.
8. Open sterilized tool kit and lay tools into the sterile field.
9. Prepare buprenorphine (working solution: 0.005 mg/mL; Dose = 0.01 mL/g body weight) for post-operative analgesia.

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Antibodies          |        |            |
| Rabbit anti-p-p44/42 MAPK Erk1/2 (1:1000) | Cell Signaling Technology | Cat#4370 |
| Mouse anti-p44/42 MAPK Erk1/2 (1:2000) | Cell Signaling Technology | Cat#9107 |
| IRDye 680RD (1: 15,000) | LI-COR Biosciences | Cat#926-68073 |
| IRDye 800CW (1: 15,000) | LI-COR Biosciences | Cat#926-32212 |
| Chemicals, peptides, and recombinant proteins |        |            |
| U0126               | MilliporeSigma | SKU:662005 |
| Dimethyl sulfoxide (DMSO)* | Fisher Scientific | Cas#67-68-5 |
| Bovine Serum Albumin | Sigma-Aldrich | Cat#A9647 |
| Recombinant FGFI    | Prospec Protein Specialists | Cat#CYT-528 |
| Tissue Protein Extraction Reagent (T-PER) | Thermo Fisher Scientific | Cat#78501 |
| Halt™ Protease and Phosphatase Inhibitor Cocktail (100X) | Thermo Fisher Scientific | Cat#78440 |
| Phenylmethylsulfonyl fluoride (PMSF)* | RPI Research Products International | SKU P20270-5.0 |
| Saline (0.9% Sodium Chloride) | Hospira | NDC 0409-4888-02 |
| Sterile Water        | Hospira | NDC 0409-4887-24 |
| Intercept Blocking Buffer | LI-COR Biosciences | Cat#927-60001 |
| 4X protein loading buffer | LI-COR Biosciences | Cat#928-40004 |
| B-mercaptoethanol*   | Sigma-Aldrich | Cas#60-24-2 |
| Chameleon Duo Pre-Stained Ladder | LI-COR Biosciences | Cat#928-60000 |
| Methanol*            | Fisher Scientific | Cat#A4125K |
| Tris                 | Fisher Scientific | Cat#BP152-1 |
| Glycine              | Fisher Scientific | Cat#BP381-1 |
| Isoflurane*          | Piramal Critical Care | NDC 66794-017-10 |
| Buprenorphine*       | Par Pharmaceuticals | NDC 42023-179-05 |
| Tween-20            | Sigma-Aldrich | Cat#T379 |
| Bolt™ Running Buffer | Thermo Fisher Scientific | Cat#B0001 |
| Critical commercial assays |        |            |
| BCA Protein Assay Kit | Thermo Scientific | Cat#23225 |
| Revert 700 Total protein Stain Kit | LI-COR Biosciences | P/N: 926-11010 |
| Experimental models: Organisms/strains |        |            |
| C57BL/6J mouse       | The Jackson Laboratory | Stock No. 000664 |
| B6.V-Lepob/J homozygous mouse | The Jackson Laboratory | Stock No. 000632 |
| Other                |        |            |
| Hair net~            | Fisher Scientific | Cat#19-170-900 |
| Surgical mask~       | WVR     | Cat#41004-670 |
| Sterile gown~        | Fisher Scientific | USM51050CF |
| Sterile gloves~      | Kimberly-Clark Professional | Product#56844 |
| Eye lubrication~     | Major Pharmaceutical | NDC 0904-6488-38 |
| Scalpel blade~       | Aspen Bard Parker | Cat#371150 |
| Betadine swabs~      | Fisher Scientific | Cat#51125 |
| Ethanol wipes~       | Fisher Scientific | Cat#22-363-750 |
| Cotton swabs~        | Puritan  | SKU:867WC |
| Gauze (4 x 4)~       | Covidien | Product#441215 |
| Small plastic cups~  | Fisher Scientific | Cat#FB012919 |
| 3 mL syringe ~       | BD      | SKU:309656 |

(Continued on next page)
## MATERIALS AND EQUIPMENT

### U0126 Osmotic pump infusion (Fills n=15 osmotic pumps)

| Reagent                  | Final concentration | Amount  |
|--------------------------|---------------------|---------|
| U0126                    | 30 mM               | 30 mg   |
| DMSO (50% DMSO:50% saline)| n/a                | 2,478 µL|
| Total                    | 30 mM               | 2,478 µL|

Prepare solution immediately before filling the osmotic pump.
## U0126 acute injection

| Reagent                          | Final concentration | Amount   |
|----------------------------------|---------------------|----------|
| U0126                            | 2.5 μg/μL           | 100 μg   |
| DMSO (50% DMSO:50% saline)       | n/a                 | 50 μL    |
| **Total**                        | 2.5 μg/μL           | 50 μL    |

Prepare solution immediately prior to inject and keep at room temperature 68 degree F between injections.

## Fibroblast growth factor 1 (FGF1)

| Reagent          | Final concentration | Amount |
|------------------|---------------------|--------|
| FGF1             | 1.5 μg/μL           | 50 μg  |
| Sterile Water    | n/a                 | 33.3 μL|
| **Total**        | 1.5 μg/μL           | 50 μL  |

Prepare solution immediately prior to inject and keep on wet ice between injections.

## Protein Lysis Buffer

| Reagent                           | Final concentration | Amount   |
|-----------------------------------|---------------------|----------|
| T-Per                             | N/A                 | 200 μL/sample |
| PMSF                              | 1 mM                | 10 μL/mL  |
| Phosphatase and Protease Inhibitor| 1x                  | 10 μL/mL  |
| **Total**                         | N/A                 | 220 μL   |

Prepare solution immediately prior to protein isolation.

## Protein Loader Buffer

| Reagent                                     | Final concentration | Amount   |
|---------------------------------------------|---------------------|----------|
| 4X protein loading buffer                   | 2X                  | 475 μL   |
| Sterile Water                               | N/A                 | 475 μL   |
| B-mercaptoethanol                           | 715 mM (5%)         | 50 μL    |
| **Total**                                   | N/A                 | 1,000 μL |

Prepare solution immediately prior adding to protein samples.

## Transfer Buffer

| Reagent       | Final concentration | Amount   |
|---------------|---------------------|----------|
| Tris          | 25 mM               | 3.03 g/L |
| Glycine       | 192 mM              | 14.4 g/L |
| Methanol      | 20%                 | 200 mL   |
| Sterile Water | N/A                 | Quantity sufficient |
| **Total**     | N/A                 | 1,000 mL |

Transfer buffer can be stored at 4°C for up to a month.

## Wash Buffer

| Reagent       | Final concentration | Amount   |
|---------------|---------------------|----------|
| NaCl          | 150 mM              | 8 g/L    |
| KCl           | 2 mM                | 0.2 g/L  |
| Tris Base     | 25 mM               | 3 g/L    |
| Tween-20      | 0.1%                | 1 mL     |
| Sterile Water | N/A                 | Quantity sufficient |
| **Total**     | N/A                 | 1,000 mL |

Wash Buffer Store at Room Temperature 68 degree F and used up to 6 months.
CRITICAL: Chemicals marked with * in the key resources table are hazardous or toxic. Caution should be taken while using these reagents and Chemical Safety Datasheets should be followed.

Alternatives: Although this protocol employs a dual-port guide cannula, a single port guide cannula and an osmotic pump connected to the icv injector can also be used. In this case, the icv injections are performed first, followed by connecting the injector to the catheter and cementing the injector with acrylic for continuous infusion as outlined in Figure 3. Products for this alternative are marked with #. Bone screws and acrylic are used to secure the guide cannula in this protocol although dental cement is a suitable alternative (G-BOND, GC America 002277 and G-ænialTM Universal Flo). Additionally, this protocol uses near-infrared fluorescent western blot to quantify levels of both phospho-ERK and ERK proteins in tissue extracts in the same assay. However, western blot using traditional chemiluminescence is a suitable alternative.

STEP-BY-STEP METHOD DETAILS

Implant dual-port guide cannula

Prepare mouse for surgery

© Timing: 10–15 min

1. Prepare 8-week-old C57BL/6J male mice.

Note: Animals are housed individually under specific pathogen-free conditions in a temperature controlled environment with either a 12 h: 12 h or 14 h:10 h light: dark cycle.

   a. All animal procedures are performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at the University of Washington.

2. Record body weight and calculate buprenorphine dosage.
3. Set induction chamber to 2% isoflurane.
4. Place mouse inside the induction chamber for a duration of 2–5 min.
5. Once anesthetized, with an electric shaver, remove hair from the incision area on top of the head.
6. Apply eye lubrication to keep eyes moist during the surgery.
7. Set surgical station isoflurane flow to 1%–2%.
8. Place mouse in stereotaxic apparatus by opening the mouth with non-sterile thick forceps moving the tongue out of the way, and placing the top teeth in the hole on the mouth plate. (Figure 1A).
9. Pull the nose cone over the mouth.
10. Place the animal in the ear bars.
11. Tighten the nose cone and the ear bars to ensure the head is firmly in place.
12. Ensure the depth of anesthesia by performing a toe pinch. The mouse should not react.

Skin preparation

© Timing: 2 min

13. Sterilize the shaved incision area with 3 alternating scrubs of betadine and alcohol wipes.
14. Begin sterilizing scrubs along what will be the incision line in a circular motion and extend outward.
Implant third ventricle cannula

*Timing: 20 min*

15. Replace gloves with sterile surgical gloves for surgery.
16. Using sterile forceps, place the guide cannula in the holder on the stereotaxic device to ensure the cannula tip is perpendicular, straight down by viewing it from multiple angles. (Figure 1B).
17. Connect a 1 cm vinyl catheter to the osmotic pump port.
18. Seal the end of the catheter by melting the tube close with forceps just removed from the hot bead sterilizer.
19. Using dog-tooth forceps in one hand, grasp the skin between the eyes. On the other hand, use a scalpel to make a small incision along the midline in the center of the head.
20. Use cotton swabs to clean the skull and, by opening using lateral traction, the incision of the skin will stay open.
21. Use the guide cannula to level the skull.
   a. Move the tip of the guide cannula to lambda (Figure 1C), touch the skull and zero all the coordinates on the controller by pressing reset.
   b. Move the guide cannula to bregma and touch the skull. Look at the Z coordinate to determine if the distance is within 0.1 mm, indicating the skull is level.
22. Once level, touch the tip of the guide cannula at bregma and zero all the coordinates.
23. Move the guide cannula to the 3V coordinates -1.8 mm posterior to bregma and midline zero.
   a. Mark the coordinate on the skull for the guide cannula (Figure 1C).
24. Move the guide arm out of the way.
25. Drill three holes for the screws ensuring that the holes are from the sutures on the skull and screws will not block placement of the guide cannula (Figure 1C).
   a. It is important to use light pressure to drill through the skull to ensure drill bit doesn’t subsequently damage the brain by going too deep.
26. Implant the screws, in one hand hold the curved forceps with a small bone screw. In the other hand, use the screwdriver to screw in the screws.

△ CRITICAL: Ensure the head is secure in ear bars to prevent any movement of the head while placing the screws.

27. Once the screws are in place, move the cannula back into place, touch the skull and ensure the guide cannula lines up with the mark made.
28. Drill a hole for the guide cannula, then lower the guide cannula to -5 mm. The base of the can-
nula should be 0.3 mm off the skull surface.
   a. Coordinates for dual-port cannula.
      i. A/P: -1.8.
      ii. M/L: 0.
      iii D/V: -5.00.
   b. If bleeding occurs during guide cannula placement, use a sterile cotton tip applicator to
      apply light pressure until bleeding has stopped.

   △ CRITICAL: The cannula is implanted directly through the superior sagittal sinus and there-
   fore bleeding is expected. Direct pressure with a sterile cotton-tipped applicator applied
   for 1–2 min, or sterile gauze pads wrapped around the cannula can be used to stop the
   bleed. Ensure that bleeding has completely stopped prior to cementing the cannula in
   place.

29. Cement cannula in place (Figure 1D).
   a. Mix the acrylic and Ortho-Jet powder in a 1:2 ratio in a small plastic cup. Remove the needle
      on a 3 mL twist top syringe, fill the syringe with the acrylic solution and twist on the capped
      needle.
   b. Uncap the needle and squeeze the acrylic on the skull covering the 3 implanted screws fully
      and bottom 1/2 of the guide cannula.
   c. Let acrylic dry completely (approximately 10–15 min).

30. Remove the cannula holder and ensure the cannula is not moving out of place. Troubleshooting 1.
31. Place a long dummy cannula obturator in the guide cannula and screw into place.
32. Clean tools with alcohol wipes before placing into bead sterilizer if multiple animals are under-
    going surgery.

Postoperative care

   ★ Timing: 5–10 min

33. Remove the mouse from the nose cone and place it on a heating pad.
34. When heart rate and breathing have increased sufficiently and before the animal is mobile,
    administer buprenorphine subcutaneously. Troubleshooting 2.
35. Return animal to clean cage on a heating pad. Make sure the animal has access to water or gel
    and food.
36. Allow the mouse to recover for a week before performing injections or implanting an osmotic
    pump.

   △ CRITICAL: Standard Allentown shoebox cages are used for housing mice after surgery.
   Monitor mice daily and replace dummy cannula if it is removed.

Osmotic pump priming and implanting

   ★ Timing: 1–2 days

Preparation of micro-osmotic pump – prime the osmotic pump the day before surgery.

37. Cut vinyl catheter tubing into 5 cm pieces using sterilized scissors.
38. In a biosafety cabinet, create a sterile field to prepare osmotic pumps. Troubleshooting 3.
39. Drop pump flow moderator and catheter into the sterile field.
40. Adjust the metal tube in the flow moderator so that 3 mm is visible above the white cap.
41. Connect the 3 cm catheter tubing to the flow moderator.
42. Fill one sterile 1 mL syringe with U0126 and a second 1 mL syringe with vehicle.
43. Connect the filling needle to the 1 mL syringe.
44. Insert the filling needle to the bottom of the pump. Slowly fill the pump while withdrawing the needle until a small bubble of liquid forms outside the pump.
45. Fill the catheter tubing-flow moderator from the catheter tubing end.
46. Insert the flow moderator into the osmotic pump.
47. Prime the osmotic pump in a sterile 15 mL falcon tube fully submersed in sterile saline solution at 37°C for 24 h. (Figure 2A) Troubleshooting 3.

**Note:** Refer to manufacturer’s protocol for additional details.
Preparation for micro-osmotic pump implantation

- **Timing:** 20 min

48. Sterilize surgical tools, gauze for surgery, icv tubing, and injectors. (Figure 2B).
49. Set up nose cone by connecting oxygen and isoflurane.
50. Turn on the bead sterilizer.
51. Create a sterile field.
52. Drop gauze, scalpel, and surgical supplies onto a sterile field.
53. Open sterilized tool kit and lay tools into the sterile field.
54. Prepare buprenorphine for postoperative care.

Prepare mouse

- **Timing:** 7–10 min

55. Record body weight and calculate buprenorphine dosage.
56. Set induction chamber to 2% isoflurane.
57. Place mouse inside induction chamber.
58. Once anesthetized, remove hair from the incision area on the back between the scapulae with an electric shaver.
59. Apply eye lubrication to keep eyes moist during the surgery.
60. Set surgical station isoflurane flow to 1%–2%.
61. Place mouse in the nose cone.
62. Ensure the depth of anesthesia by performing a toe pinch. The mouse should not react.
63. Clean the shaved incision area with three alternating scrubs of betadine and alcohol wipes.
64. Begin along what will be the incision line in a circular motion and extend outward.
65. Drape mouse with a sterile sheet containing a small window for the surgical area.

Implant osmotic pump

- **Timing:** 5–7 min

66. Use small scissors to make a small incision the diameter of the osmotic pump between the scapulae.
67. Create a pocket for the pump under the skin by gently inserting thick forceps into the incision the same length as the osmotic pump. Open and close the forceps to spread the subcutaneous tissue.
68. Insert a filled pump connected to vinyl catheter tubing into the pocket with the catheter and flow moderator facing the guide cannula. (Figure 2D).
   a. The pump should rest below the incision to one side of the spine.
69. Carefully remove the tubing connected to the infusion port on the guide cannula using forceps.
70. Cut the catheter tubing from the osmotic pump to fit the length (ca. 3 cm) and connect tubing to the guide cannula. (Figure 2E).

Close incision

- **Timing:** 2–5 min

71. Place 2–4 interrupted sutures, closing the skin around the catheter tubing. (Figure 2F).
   a. Inspect the incision site to ensure it is completely closed.
**Administer icv injection**

*Administer icv injections*

- **Timing:** 10 min

72. Prepare icv injection Hamilton syringes for use, one for FGF1 and one for U0126.
   a. Drop the sterile icv tubing and the injectors into sterile field.
   b. Connect one end of icv tubing to the 10 ul Hamilton syringe and remove the plunger.
   c. Fill a 3 mL syringe with sterile water and attach a 25 gauge needle.
   d. Connect the syringe to the icv tubing and fill the icv tubing and Hamilton syringe with sterile water.
   e. Replace the Hamilton syringe plunger.
   f. Disconnect the syringe and connect the injector.
   g. Pull 1 ul of air into the tube to separate the sterile water and the drug.
   h. Place the injector into the drug and pull in 4–5 ul.

73. While mouse is under anesthesia place injector into the U0126 solution and pull out the plunger to fill the icv tubing.

74. Remove the long dummy cannula obturator from the guide cannula and insert the injector (Figure 2C) with the syringe filled with U0126.

75. Depress the plunger to administer U0126 (2 μL/min), remove the injector and replace the dummy cannula obturator.

△ **CRITICAL:** Watch the air bubble move in the icv tubing to ensure fluid is flowing through the cannula during the icv injection. Troubleshooting 4.

76. Wait 10 min and repeat steps 72 and 75 with the syringe filled with FGF1.

After the icv injections are complete replace with the short dummy cannula to create passage for flow through the osmotic pump.

△ **CRITICAL:** The short dummy cannula ensures the osmotic pump flow is not obstructed.

**Postoperative care**

- **Timing:** 5–10 min

77. Remove the animal from nose cone and place on a heating pad.

78. When heart rate and breathing have increased sufficiently and before the animal is mobile, administer buprenorphine subcutaneously. Troubleshooting 2.

79. Return animal to the cage on a heating pad. Make sure the animal has access to gel or water and food.

**Western blot validation**

*Isolate hypothalamus for western blot*

- **Timing:** 10–15 min

80. Sacrifice the mouse 24 h post icv injection/osmotic pump implant.
81. Use CO₂ to euthanize the animal.
82. Carefully dissect the brain from the skull.
83. Place the whole brain into an ice-cold metal mouse brain matrix. (Figure 3A).
84. Use two new razor blades to cut a 1.5 mm coronal section of the hypothalamus.
   a. Use the Circle of Willis as a marker for the locations of the razor blades. (Figure 3B).
85. Place the coronal section on a metal block on ice.
86. Punch out the mediobasal hypothalamus with a 3 mm tissue punch. (Figure 3C).
87. Place the mediobasal hypothalamus into a labeled tube.
   a. Place a hole in the top of the tube to release the pressure to avoid tube rupturing.
88. Drop tube to snap freeze in liquid nitrogen.
   a. Samples can stay in liquid nitrogen until all samples are collected.
89. Store at −80°C until ready to process or process immediately.

△ CRITICAL: Remove osmotic pump and measure the volume of remaining liquid to ensure adequate flow of drug occurred.

● Pause point: Tissue can be stored at −80°C for up to 6 months.

Isolate protein from hypothalamus

○ Timing: 20–30 min

90. Place each sample on ice and pipet 200 μL of cold Lysis buffer.
91. Set sonicator to Duty cycle 50% and set power to 5.

△ CRITICAL: Protect your ears by wearing noise-canceling earmuffs.
92. Sonicate the sample with three pulses five-second each to ensure the tissue has been fully homogenized.
93. Clean sonicator between samples with deionized water and Lysis buffer.
94. Centrifuge samples 10,000 x rcf for 15 min at 4°C.
95. Transfer supernatant, containing the proteins of interest, into a new tube on ice.
96. Store protein at –80°C.

Pause point: Protein can be stored at –80°C for up to 6 months.

97. Measure protein concentration by following the manufacturer’s protocol for BCA protein assay kit.

Prepare protein samples and run gel

@ Timing: 10–25 min

98. Calculate total protein concentration to load on the gel for proper concentration for “linear range.”
99. Prepare samples to load 15 μL with 3 μg protein per well.
100. Add correct concentration of Protein Sample loading buffer.
101. Heat samples at 100°C for 5 min.

Running and transferring the gel

@ Timing: 2–2.5 h

102. Place 26 well 10% criterion gel in the Criterion cell buffer tank and fill the tank with Bolt™ Running Buffer.

△ CRITICAL: Remove the white tap strip across the bottom of the gel.

103. Load 5 μl of the Chameleon Duo Pre-Stained Ladder into the first well.
104. Pipet 15 μl of each sample into the gel to avoid pipetting bubbles into the well.
105. Connect the Criterion cell to PowerPac and run electrophoresis at 200 V for 25 min.
106. While the gel is running, prepare for the transfer.
107. Submerge the PVDF membrane cut the exact size of the gel in methanol to saturate it completely.
108. Soak blotting papers and sponge pads in cold transfer buffer.
109. Carefully remove the gel from the plastic casing.
110. Assemble the Bio-rad submerged electrophoretic protein transfer apparatus containing both the gel and the PVDF membrane according to bio-rad Instructions.
111. Place ice pack inside the transfer chamber.
112. Run the transfer chamber at 100V for 45–60 min in a cold room.

△ CRITICAL: Ensure all the running and transfer apparatus are clean.

Incubate and image membrane

@ Timing: 1 day

113. Remove membrane from transfer apparatus.
114. Follow the Total Protein Stain manufacture protocol.
   a. Rinse the membrane in ultra-pure water.
   b. Incubate in 5 mL of REVERT Total Protein Stain solution for 5 min with gentle rocking.
c. Decant Total Protein Stain Solution completely.

d. Rinse membrane 2 × 30 s with 5 mL of Wash Solution. Briefly rinse membrane in water.

e. Image membrane immediately in 700 nm channel with Odyssey FC according to the manufacture protocol. Troubleshooting 5.

f. Incubate the membrane in 5 mL of REVERT Reversal solution for 5–10 min with gentle shaking. Do not reverse for longer than 10 min.

g. Rinse membrane briefly with water and proceed to block.

115. Block membrane in blocking Intercept Blocking Buffer for 1 h at room temperature 68 degree F (RT).

116. Wash membrane 1 × 15 min, 2 × 5 min at RT, replacing the wash buffer each time.

117. Incubate blot in pERK 1:1,000 and total ERK 1:2,000 overnight 12–14 h in cold room gentle shaking.

118. Rinse membrane with wash buffer 1 × 15 min, 2 × 5 min at RT, replacing the wash buffer each time.

119. Incubate blot with secondary antibody IRDye 800CW 1: 15,000 and IRDye 680RD 1:15,000 in wash buffer + 0.01% SDS for 1 h at RT gently rocking.

120. Wash membrane with wash buffer 1 × 15 min, 2 × 5 min at RT with wash buffer, and rinse membrane with wash buffer.

121. Detect using Odyssey FC for 700 and 800 channels for 2 min. Troubleshooting 5.

Note: Refer to manufacture protocol and online resources.

△ CRITICAL: The Odyssey FC is sensitive to contamination, leading to excess fluorescence on the membrane during detection. To avoid nonspecific fluorescence, ensure incubation boxes and trays used for the western blot are clean before use.

EXPECTED OUTCOMES

To investigate if FGF1 induced activation of the hypothalamic MAPK/ERK signaling pathway in male C57BL/J6 mice, we stereotaxically implanted a guide cannula targeting the third ventricle in the hypothalamus. After one week, we gave an icv injection of an initial ‘loading dose’ of U0126 or vehicle, followed by icv FGF1 injection and subsequent implantation an osmotic pump containing U0126 or vehicle that was and connected to the cannula. Surprisingly, FGF1 induced activation of MAPK/ERK signaling lasted for at least 24 h in mice receiving icv vehicle (rather than U0126). To block activation this response, the MAPK inhibitor U0126 was infused via osmotic minipump into the third ventricle at a rate of 1 ul per h for 24 h. Continuous icv infusion was required due to the short 1/2 life of U0126 that made conventional icv injections ineffective at blocking FGF1 action. Mice were sacrificed 24 h post-injection and protein was isolated from the mediobasal hypothalamus. Using near-infrared fluorescence western blot to quantify hypothalamic levels of pERK, a biomarker of MAPK/ERK pathway activity, we confirmed that FGF1-induced MAPK/ERK signaling was blocked in the hypothalamus by continuous infusion of U0126 into the adjacent 3rd ventricle for 24 h (Figure 4A).

To determine if pharmacological inhibition of MAPK/ERK signaling blocked the sustained antidiabetic action induced by icv injection of FGF1, we repeated the above study in adult male, diabetic Lep<sup>ob/ob</sup> mice and monitored blood glucose levels daily for 15 days (Figure 4B). To control for the potential confounding effect of DMSO (vehicle used to dilute U0126) or U0126 alone, we included additional groups with these treatments as controls. As previously reported, central injection of FGF1 induced sustained glucose-lowering in diabetic Lep<sup>ob/ob</sup> mice, an effect that was not impacted by co-infusion of DMSO. In contrast, 24-h icv infusion of U0126 following icv injection of FGF1 blocked the sustained glucose-lowering action of centrally administered FGF1. As expected, neither icv infusion of DMSO vehicle nor infusion of U0126 for 24 h had a significant effect on blood glucose in diabetic Lep<sup>ob/ob</sup> mice that did not receive an icv injection of FGF1 (Figure 4C). Taken together, these results show that hypothalamic ERK1/2 activation is required for sustained remission of diabetic hyperglycemia induced by the central action of FGF1. Refer to Brown et al. (2021) for full study.
LIMITATIONS

A significant limitation of this protocol is that it requires multiple surgeries that collectively increase post-surgical morbidity and mortality. To minimize this risk, osmotic pump insertion and icv injection is performed following recovery from cannula implantation. Additionally, for experiment that require studying the blood glucose in animal the osmotic pump should be removed 24 h after icv injection of FGF1.

TROUBLESHOOTING

Problem 1
Failure to implant/secure guide cannula (step 30).

Potential solution
Ensure the mouse is fixed in the stereotactic apparatus.

Ear bars should hold the head firmly in place preventing movement from left to right.

Top incisor teeth should sit in the incisor bar and nose cone tightened around the nose.

Ensure the cannula is fixed to the skull.

The skull should be completely dry and bleeding is stopped before applying the cement.

Acrylic solution should be sufficient to cover the bone screws completely.

Ensure the acrylic is dry and hard prior to removing the stereotaxic arm.

Figure 4. Pharmacological inhibition of MAPK/ERK signaling blocked the sustained antidiabetic action induced by icv injection of FGF1

(A) Representative western blot (left panel) and quantitative comparison of phosphorylated (red) and total ERK1/2 (green) and total protein (red) (right panel) from hypothalamic punches from adult male C57Bl6J mice 24 h after icv injection of FGF1 or vehicle into the 3rd ventricle (3V) followed by continuous infusion via osmotic pump of 30 mM 1 μL/h U0126 or DMSO for 24 h.

(B) Strategy for MAPK/ERK inhibition by continuous 3V infusion of U0126 or Vehicle DMSO for 24 h followed by disconnection of osmotic pump and metabolic phenotyping image created with BioRender.com.

(C) Blood glucose measured in diabetic Lepob/ob mice (n=5–8/group repeated measures nparLD ANOVA test statistic treatment ~4.99 df=2.67 p=0.002) measured for 15 days post-treatment with icv injection of either saline vehicle or FGF1 (3 μg) followed by a 24 h continuous infusion of U0126 or DMSO vehicle into the third ventricle. Data are represented as mean ±SEM.
Problem 2
Death of mouse (steps 34 and 78).

Potential solution
Monitor the mouse respiration during the procedures.

Place mouse on heating past post procedure to prevent hypothermia.

Ensure the mouse has access to food and water.

Problem 3
Failure to prepare osmotic pump (steps 38 and 47).

Potential solution
When preparing and implanting the osmotic pump everything should remain sterile.

Completely fill osmotic pumps to ensure no air bubbles.

Problem 4
Obstruction in cannula during icv injection (step 75).

Potential solution
Remove icv injector.

Replace long dummy cannula and secure fully on.

Screw long dummy cannula off and on 2–3 times.

Problem 5
Contamination on the western blot (steps 114 and 121).

Potential solution
Completely wash the running and transfer chamber along with all the trays.

Make sure to use ultra-pure water when rising the membrane.

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jarrad Scarlett (Jarrad.Scarlett@seattlechildrens.org).

Materials availability
This study did not generate new unique reagents.

Data and code availability
This study did not generate datasets.

ACKNOWLEDGMENTS
J.M.B. was supported by National Heart, Lung, and Blood Institute T32 training grant HL-007312 and the Diabetes Research Center Samuel and Althea Stroum Endowed Graduate Fellowship at the University of Washington. This work was supported by NIH-NIDDK grants K08DK114474 (J.M.S.), R03 DK128383 (J.M.S.), R01DK101997 (M.W.S.), R01DK089056 (G.J.M.), R01DK124238 (G.J.M.), and R01DK083042 (G.J.M. and M.W.S.), and an American Diabetes Association Innovative
Basic Science Award (ADA; G.J.M.). This work was also supported by the NIH-NIDDK–funded Nutrition Obesity Research Center (NORC; P30DK035816) and the Diabetes Research Center (DRC; P30DK017047) at the University of Washington. Additional funding to support these studies was provided to J.M.S. by the Department of Defense (DoD W81XWH2110635) and UW Royalty Research Fund (RRF; A139339). Funding was also provided to M.W.S. by Novo Nordisk (CMS-431104) and to J.M.B and M.A.B. by the Novo Nordisk Foundation Center for Basic Metabolic Research, which is an independent research center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (NNF10CC1016515).

AUTHOR CONTRIBUTIONS
J.B., B.P., and J.S. performed the experiments. J.B., B.P., N.A., G.M., M.S., and J.S. designed the experiments. J.B., B.P., N.A., M.S., and J.S. wrote and revised the manuscript. All authors read, revised, and approved the manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
Bentsen, M.A., Rausch, D.M., Mirzadeh, Z., Muta, K., Scarlett, J.M., Brown, J.M., Herranz-Pérez, V., Baquero, A.F., Thompson, J., Alounge, K.M., et al. (2020). Transcriptomic analysis links diverse hypothalamic cell types to fibroblast growth factor 1-induced sustained diabetes remission. Nat. Commun. 11, 4458.

Brown, J.M., Bentsen, M.A., Rausch, D.M., Phan, B.A., Wieck, D., Wasanwala, H., Matsen, M.E., Acharya, N., Richardson, N.E., Zhao, X., et al. (2021). Role of hypothalamic MAPK/ERK signaling and central action of FGF1 in diabetes remission. iScience 24, 102944.

Brown, J.M., Scarlett, J.M., Matsen, M.E., Nguyen, H.T., Secher, A.L., Jorgensen, R., Morton, G.J., and Schwartz, M.W. (2019). The hypothalamic arcuate nucleus–median eminence is a target for sustained diabetes remission induced by fibroblast growth factor 1. Diabetes 68, 1054–1061.

Scarlett, J.M., Muta, K., Brown, J.M., Rojas, J.M., Matsen, M.E., Acharya, N.K., Secher, A., Ingvorsen, C., Jorgensen, R., Høeg-Jensen, T., et al. (2019). Peripheral mechanisms mediating the sustained antidiabetic action of FGF1 in the brain. Diabetes 68, 654.

Scarlett, J.M., Rojas, J.M., Matsen, M.E., Kasayla, K.J., Stefanovski, D., Bergman, R.N., Nguyen, H.T., Dorfman, M.D., Lantier, L., Wasserman, D.H., et al. (2016). Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents. Nat. Med. 22, 800–806.